Amoéba is consolidating its finances to support its development

Amoéba, a company specializing in biological solutions, has announced a €4 million capital increase through a private placement, backed by Vatel Capital. The share price is €0.75, representing a 20% discount to the recent market average. The company has also reached an agreement with Nice & Green to extend the maturity of its debt to 2029, providing it with greater flexibility. This funding will support Amoéba's industrial and commercial expansion, particularly following the order from its partner Koppert.

The refinancing, combined with the funds raised, will allow Amoéba to focus on the commercial development of its biocontrol solution. The company hopes to maximize its growth despite an uncertain economic environment. By securing sufficient financial resources, Amoéba aims to strengthen its position in the biocontrol and cosmetics market, optimizing profitability for its partners and shareholders.